PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · see citing works

Cerebral organoids model human brain development and microcephaly

Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · see citing works

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416 · see citing works

MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease

Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · see citing works

NAFLD: A multisystem disease

Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,082 · see citing works

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

Human Fatty Liver Disease: Old Questions and New Insights

Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · see citing works

Sex and gender: modifiers of health, disease, and medicine

Mauvais-Jarvis, F., Bairey Merz, N., Barnes, P. J., Brinton, R. D., Carrero, J.-J., DeMeo, D. L., De Vries, G. J., Epperson, C. N., Govindan, R., Klein, S. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31561-0 · Cited by 2,001 · see citing works

Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis

Takasato, M., Er, P. X., Chiu, H. S., Maier, B., Baillie, G. J., Ferguson, C., Parton, R. G., Wolvetang, E. J., Roost, M. S., Chuva de Sousa Lopes, S. M., et al. (2015) · Nature · doi:10.1038/nature15695 · Cited by 1,627 · see citing works

Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver

Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619 · see citing works

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483 · see citing works

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,381 · see citing works

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., Dulai, P. S., Caussy, C., Bettencourt, R., Highlander, S. K., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.001 · Cited by 1,123 · see citing works

Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents

Lavine, J. E. (2011) · JAMA · doi:10.1001/jama.2011.520 · Cited by 1,105 · see citing works

Epidemiology of Non-Alcoholic Fatty Liver Disease

Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026 · see citing works

A Protein-Truncating <i>HSD17B13</i> Variant and Protection from Chronic Liver Disease

Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · see citing works

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach

Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696 · see citing works

Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)

Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · see citing works

Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease†

Valenti, L., Al‐Serri, A., Daly, A. K., Galmozzi, E., Rametta, R., Dongiovanni, P., Nobili, V., Mozzi, E., Roviaro, G., Vanni, E., et al. (2010) · Hepatology · doi:10.1002/hep.23622 · Cited by 651 · see citing works

The epidemiology of non‐alcoholic fatty liver disease

Bellentani, S. (2017) · Liver International · doi:10.1111/liv.13299 · Cited by 607 · see citing works

Cellular uptake and trafficking of antisense oligonucleotides

Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · see citing works

Human Intestinal Organoids Maintain Self-Renewal Capacity and Cellular Diversity in Niche-Inspired Culture Condition

Fujii, M., Matano, M., Toshimitsu, K., Takano, A., Mikami, Y., Nishikori, S., Sugimoto, S., & Sato, T. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.016 · Cited by 558 · see citing works

Near Completely Humanized Liver in Mice Shows Human-Type Metabolic Responses to Drugs

Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., Tachibana, A., Soeno, Y., Asahina, K., Hino, H., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63352-4 · Cited by 548 · see citing works

Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids

Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.007 · Cited by 537 · see citing works

ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION

Chan, J. H. P., Lim, S., & Wong, W. S. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 431 · see citing works

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Younossi, Z. M., Loomba, R. S., Anstee, Q. M., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., et al. (2017) · Hepatology · doi:10.1002/hep.29721 · Cited by 431 · see citing works

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Hepatology

Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · see citing works

Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci

Stender, S., Kozlitina, J., Nordestgaard, B. G., Tybjærg‐Hansen, A., Hobbs, H. H., & Cohen, J. C. (2017) · Nature Genetics · doi:10.1038/ng.3855 · Cited by 401 · see citing works

MAFLD identifies patients with significant hepatic fibrosis better than NAFLD

Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401 · see citing works

Update on NAFLD genetics: From new variants to the clinic

Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393 · see citing works

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity

Sookoian, S. C., Castaño, G. O., Burgueño, A. L., Gianotti, T. F., Rosselli, M. S., & Pirola, C. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900013-jlr200 · Cited by 367 · see citing works

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338 · see citing works

Antisense Oligonucleotide Therapies

Frazier, K. S. (2014) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 335 · see citing works

Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease

Huang, Y., Cohen, J. C., & Hobbs, H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.290114 · Cited by 312 · see citing works

17‐Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease

Ma, Y., Belyaeva, O. V., Brown, P. M., Fujita, K., Valles, K., Karki, S., de Boer, Y. S., Koh, C., Chen, Y., Du, X., et al. (2018) · Hepatology · doi:10.1002/hep.30350 · Cited by 310 · see citing works

The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

BasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302 · see citing works

Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene

Kantartzis, K., Peter, A., Machicao, F. E., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 299 · see citing works

PNPLA3 gene in liver diseases

Trépo, E., Romeo, S., Zucman‐Rossi, J., & Nahon, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.011 · Cited by 290 · see citing works

Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis

BasuRay, S., Wang, Y., Šmagris, Ē., Cohen, J. C., & Hobbs, H. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901974116 · Cited by 285 · see citing works

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279 · see citing works

Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease

Ramli, M. N. B., Lim, Y. S., Koe, C. T., Demircioglu, D., Tng, W., Gonzales, K. A. U., Tan, C. P., Szczerbinska, I., Liang, H., Soe, E. L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.010 · Cited by 278 · see citing works

Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial

Foster, T., Budoff, M. J., Saab, S., Ahmadi, N., Gordon, C., & Guerci, A. D. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.299 · Cited by 260 · see citing works

RNA therapeutics: RNAi and antisense mechanisms and clinical applications

Chery, J. (2016) · Postdoc Journal · doi:10.14304/surya.jpr.v4n7.5 · Cited by 238 · see citing works

Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes

Cholankeril, G. T., Wong, R. J., Hu, M., Perumpail, R. B., Yoo, E. R., Puri, P., Younossi, Z. M., Harrison, S. A., & Ahmed, A. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4684-x · Cited by 233 · see citing works

Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients

Sookoian, S., & Pirola, C. J. (2017) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.14112 · Cited by 230 · see citing works

Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function

Pingitore, P., Pirazzi, C., Mancina, R. M., Motta, B. M., Indiveri, C., Pujia, A., Montalcini, T., Hedfalk, K., & Romeo, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.12.006 · Cited by 212 · see citing works

Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice

Lindén, D., Ahnmark, A., Pingitore, P., Ciociola, E., Ahlstedt, I., Andréasson, A., Sasidharan, K., Madeyski-Bengtson, K., Zurek, M., Mancina, R. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.013 · Cited by 211 · see citing works

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system

Hanagata, N. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30197 · Cited by 199 · see citing works

Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease

Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194 · see citing works

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis

Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.15738 · Cited by 169 · see citing works

Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids

Luukkonen, P. K., Nick, A., Hölttä‐Vuori, M., Thiele, C., Isokuortti, E., Lallukka-Brück, S. E., Zhou, Y., Hakkarainen, A., Lundbom, N. M. I., Peltonen, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127902 · Cited by 161 · see citing works

Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance

Kumashiro, N., Beddow, S. A., Vatner, D. F., Majumdar, S. K., Cantley, J. L., Guebre‐Egziabher, F., Fat, I., Guigni, B. A., Jurczak, M. J., Birkenfeld, A. L., et al. (2013) · Diabetes · doi:10.2337/db12-1311 · Cited by 153 · see citing works

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease

Grimaudo, S., Pipitone, R. M., Pennisi, G., Celsa, C., Cammà, C., Marco, V. D., Barcellona, M. R., Boemi, R., Enea, M., Giannetti, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.011 · Cited by 152 · see citing works

Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease

Pirola, C. J., Garaycoechea, M. E., Flichman, D. M., Arrese, M. A., Martino, J. S., Gazzi, C., Castaño, G. O., & Sookoian, S. C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p089953 · Cited by 141 · see citing works

Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes

Dubuquoy, C., Robichon, C., Lasnier, F., Langlois, C., Dugail, I., Foufelle, F., Girard, J. R., Burnol, A., Postic, C., & Moldes, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.024 · Cited by 139 · see citing works

Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities

Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M., & Arab, J. P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00448 · Cited by 136 · see citing works

Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease

Pelusi, S., Baselli, G., Pietrelli, A., Dongiovanni, P., Donati, B., McCain, M. V., Meroni, M., Fracanzani, A. L., Romagnoli, R., Petta, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39998-2 · Cited by 125 · see citing works

Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population

Ünalp–Arida, A., & Ruhl, C. E. (2019) · Hepatology · doi:10.1002/hep.31032 · Cited by 122 · see citing works

The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage

Donati, B., Motta, B. M., Pingitore, P., Meroni, M., Pietrelli, A., Alisi, A., Petta, S., Xing, C., Dongiovanni, P., Menico, B. D., et al. (2015) · Hepatology · doi:10.1002/hep.28370 · Cited by 121 · see citing works

Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes

Yang, A., Mottillo, E. P., Mladenovic-Lucas, L., Li, Z., & Granneman, J. G. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0066-3 · Cited by 119 · see citing works

Oligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress

Sharma, V. K., & Watts, J. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.144 · Cited by 109 · see citing works

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics

Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96 · see citing works

PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis

Perttilä, J., Samanez, C. H., Caron, S., Tanhuanpää, K., Staels, B., Yki‐Järvinen, H., & Olkkonen, V. M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00125.2011 · Cited by 87 · see citing works

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models

Kim, Y., Jo, M., Schmidt, J., Luo, X., Prakash, T. P., Zhou, T., Klein, S., Xiao, X., Post, N. M., Yin, Z., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.009 · Cited by 81 · see citing works

One-step synthesis of composite hydrogel capsules to support liver organoid generation from hiPSCs

Wang, Y., Liu, H., Zhang, M., Wang, H., Chen, W., & Qin, J. (2020) · Biomaterials Science · doi:10.1039/d0bm01085e · Cited by 78 · see citing works

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

Pardanani, A. D., Gotlib, J. R., Roberts, A. W., Wadleigh, M., Sirhan, S., Kawashima, J., Maltzman, J., Shao, L., Gupta, V. K., & Tefferi, A. (2017) · Leukemia · doi:10.1038/leu.2017.330 · Cited by 76 · see citing works

Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis

Banini, B. A., Kumar, D. P., Cazanave, S. C., Seneshaw, M., Mirshahi, F., Santhekadur, P. K., Wang, L., Guan, H.-P., Oseini, A. M., Alonso, C., et al. (2020) · Hepatology · doi:10.1002/hep.31609 · Cited by 69 · see citing works

The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease

Nobili, V., Bedogni, G., Donati, B., Alisi, A., & Valenti, L. V. C. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2013.0043 · Cited by 67 · see citing works

PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings

Mantovani, A., Taliento, A. E., Zusi, C., Baselli, G., Prati, D., Granata, S., Zaza, G., Colecchia, A., Maffeis, C., Byrne, C. D., et al. (2020) · Liver International · doi:10.1111/liv.14419 · Cited by 64 · see citing works

SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy

Kim, K. A., Jang, H., Yang, Y. R., Park, K., Seo, J.-K., Shin, I.-W., Jeon, T.-I., Ahn, S., Suh, P., Osborne, T. F., et al. (2016) · Scientific Reports · doi:10.1038/srep35732 · Cited by 58 · see citing works

A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD

Yilmaz, Y. N., Byrne, C. D., & Musso, G. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1860019 · Cited by 58 · see citing works

Redefining fatty liver disease classification in 2020

Valenti, L. V. C., & Pelusi, S. (2020) · Liver International · doi:10.1111/liv.14430 · Cited by 53 · see citing works

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets

Bianco, C., Casirati, E., Malvestiti, F., & Valenti, L. V. C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100284 · Cited by 50 · see citing works

A human liver chimeric mouse model for non-alcoholic fatty liver disease

Bissig-Choisat, B., Alves-Bezerra, M., Zorman, B., Ochsner, S. A., Barzi, M., Legras, X., Yang, D., Borowiak, M., Dean, A. M., York, R. B., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100281 · Cited by 49 · see citing works

Application of Chimeric Mice with Humanized Liver for Study of Human-Specific Drug Metabolism

Bateman, T. J., Reddy, V., Kakuni, M., Morikawa, Y., & Kumar, S. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.056978 · Cited by 44 · see citing works

A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism

Barzi, M., Pankowicz, F. P., Zorman, B., Liu, X., Legras, X. D., Yang, D., Borowiak, M., Bissig-Choisat, B., Sumazin, P., Li, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00049-x · Cited by 43 · see citing works

Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings

Schwartz, B. E., Rajagopal, V., Smith, C. J., Cohick, E., Whissell, G., Gamboa, M. E., Pai, R., Sigova, A. A., Grossman, I., Bumcrot, D. A., et al. (2020) · Cells · doi:10.3390/cells9102247 · Cited by 42 · see citing works

Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin

Rae-Whitcombe, S. M., Kennedy, D. M., Voyles, M., & Thompson, M. P. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.106 · Cited by 39 · see citing works

Mutant PNPLA3 I148M protein as pharmacological target for liver disease

Valenti, L. V. C., & Dongiovanni, P. (2017) · Hepatology · doi:10.1002/hep.29298 · Cited by 33 · see citing works

Differential Effect of Troglitazone on the Human Bile Acid Transporters, MRP2 and BSEP, in the PXB Hepatic Chimeric Mouse

Foster, J. R., Jacobsen, M. C., Kenna, J. G., Schulz-Utermoehl, T., Morikawa, Y., Salmu, J., & Wilson, I. D. (2012) · Toxicologic Pathology · doi:10.1177/0192623312447542 · Cited by 32 · see citing works

Steroid metabolism in chimeric mice with humanized liver

Lootens, L., Eenoo, P. V., Meuleman, P., Pozo, Ó. J., Renterghem, P. V., Leroux-Roels, G. G., & Delbeke, F. T. (2009) · Drug Testing and Analysis · doi:10.1002/dta.67 · Cited by 24 · see citing works

Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C

Valenti, L. V. C., Colombo, M., & Fargion, S. R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.032 · Cited by 20 · see citing works

Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease

Cespiati, A., Youngson, N. A., Tourna, A., & Valenti, L. V. C. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200122151251 · Cited by 20 · see citing works

Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice

Samuelsson, K., Pickup, K., Sarda, S., Foster, J. R., Randall, K., Abrahamsson, A., Jacobsen, M. C., Weidolf, L. O. G., & Wilson, I. D. (2014) · Xenobiotica · doi:10.3109/00498254.2013.879237 · Cited by 17 · see citing works

The SRE Motif in the Human PNPLA3 Promoter (−97 to −88 bp) Mediates Transactivational Effects of SREBP‐1c

Liang, H., Xu, J., Xu, F. L., Liu, H., Yuan, D., Yuan, S., Cai, M., Yan, J., & Weng, J. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24951 · Cited by 15 · see citing works

Reply to: “Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease”

Jamialahmadi, O., Bianco, C., Pelusi, S., Romeo, S., & Valenti, L. V. C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.030 · Cited by 12 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321 · see citing works

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02434-5 · Cited by 206 · see citing works

Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease

Cherubini, A., Torre, S. D., Pelusi, S., & Valenti, L. V. C. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.013 · Cited by 160 · see citing works

Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

Cherubini, A., Ostadreza, M., Jamialahmadi, O., Pelusi, S., Rrapaj, E., Casirati, E., Passignani, G., Norouziesfahani, M., Sinopoli, E., Baselli, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02553-8 · Cited by 136 · see citing works

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update

Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 82 · see citing works

Advancing targeted protein degradation for metabolic diseases therapy

Zhou, Q., Xiao, H., Yang, F., Wang, Y., Li, P., & Zheng, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106627 · Cited by 76 · see citing works

MASH clinical trials and drugs pipeline: An impending tsunami

Noureddin, M. (2024) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 50 · see citing works

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis

Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46 · see citing works

PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review

Boeckmans, J., Gatzios, A., Schattenberg, J. M., Koek, G. H., Rodrigues, R. M., & Vanhaecke, T. (2023) · Liver International · doi:10.1111/liv.15533 · Cited by 31 · see citing works

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 32 · see citing works

Microplastic-induced NAFLD: Hepatoprotective effects of nanosized selenium

Shen, Q., Liu, Y. J., Qiu, T. T., k, S. L., & Zhou, D. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115850 · Cited by 29 · see citing works

Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm

Chua, D., Low, Z. S., Cheam, G. X., Ng, A. S., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314762 · Cited by 30 · see citing works

PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction

Gou, Y., Wang, L., Zhao, J., Xu, X., Xu, H., Xie, F. X., Wang, Y., Feng, Y., Zhang, J., & Zhang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119681 · Cited by 25 · see citing works

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases

Zhang, G., Jiang, W., He, F., Fu, J., Xu, X. S., Luo, X., & Cao, Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae264 · Cited by 24 · see citing works

Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 25 · see citing works

Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches

Mahmoudi, S. K., Tarzemani, S., Aghajanzadeh, T., Kasravi, M., Hatami, B., Zali, M. R., & Baghaei, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01708-8 · Cited by 22 · see citing works

Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges

Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., & Gao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1639064 · Cited by 22 · see citing works

Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum

Xie, C., Yuan, Y., Wang, Y., Qi, C., Wang, W., An, C., Aikepaer, A., Zhang, Y., Zhang, G., Feng, X., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00673-5 · Cited by 26 · see citing works

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping

Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i2.92791 · Cited by 21 · see citing works

Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle‐aged individuals with metabolic dysfunction

Mantovani, A., Pelusi, S., Margarita, S., Malvestiti, F., Dell'Alma, M., Bianco, C., Ronzoni, L., Prati, D., Targher, G., & Valenti, L. V. C. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17477 · Cited by 20 · see citing works

Advances in genetic variation in metabolism-related fatty liver disease

Shi, F., Zhao, M., Zheng, S., Zheng, L., & Wang, H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1213916 · Cited by 21 · see citing works

Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis

Bharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19 · see citing works

The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists

Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 20 · see citing works

Experimental Models to Investigate PNPLA3 in Liver Steatosis

Ramandi, A., Diehl, A., Sanyal, A. J., & de Jong, Y. P. (2025) · Liver International · doi:10.1111/liv.70091 · Cited by 19 · see citing works

PNPLA3 variation and kidney disease

Mantovani, A., & Targher, G. (2024) · Liver International · doi:10.1111/liv.16010 · Cited by 15 · see citing works

PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras

Bhole, R. P., Patil, S., Kapare, H. S., Chikhale, R. V., & Gurav, S. S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266309968240621072550 · Cited by 14 · see citing works

Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD

Mercurio, G., Giacco, A., Scopigno, N., Vigliotti, M., Goglia, F., Cioffi, F., & Silvestri, E. (2025) · Nutrients · doi:10.3390/nu17071214 · Cited by 14 · see citing works

Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele

Kirchmeyer, M., Gaigneaux, A., Servais, F., Arslanow, A., Casper, M., Krawczyk, M. J., Lammert, F., & Behrmann, I. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000306 · Cited by 13 · see citing works

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

El‐Kassas, M., Awad, A., Elbadry, M., & Arab, J. P. (2024) · Seminars in Liver Disease · doi:10.1055/a-2253-9181 · Cited by 12 · see citing works

A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease

Pérez-Díaz-del-Campo, N., Dileo, E., Castelnuovo, G., Nicolosi, A., Guariglia, M., Caviglia, G. P., Rosso, C., Armandi, A., & Bugianesi, E. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.09.022 · Cited by 11 · see citing works

Effects of Diet and Exercise on Mitochondrial Health in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Role of Ceramides

McCaffrey, J. M., & Ibdah, J. A. (2025) · Nutrients · doi:10.3390/nu17182972 · Cited by 12 · see citing works

Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement

Bhattacharya, I., Maity, D. K., Kumar, A., Sarkar, S., Bhattacharya, T., Sahu, A., Sreedhar, R., & Arumugam, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04257-x · Cited by 11 · see citing works

MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk

Mostafa, A. M., Pan, Z., Yu, M., Örmecı, N., Fouad, Y. M., & Eslam, M. (2025) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s506402 · Cited by 10 · see citing works

Nonlinear association between body roundness index and metabolic dysfunction associated steatotic liver disease in nondiabetic Japanese adults

Huang, C., Gao, Z., Zhenxia, H., & Xu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-99540-5 · Cited by 9 · see citing works

Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine

Pérez-Díaz-del-Campo, N., Martínez‐Urbistondo, D., Bugianesi, E., & Martínez, J. A. (2022) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000849 · Cited by 9 · see citing works

Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression

Sonkar, R., Ma, H., & Waxman, D. J. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae057 · Cited by 7 · see citing works

Gene-based therapies for steatotic liver disease

Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 7 · see citing works

PNPLA3 I148M and Hepatocellular Carcinoma

Tavaglione, F., Pennisi, G., & Pelusi, S. (2025) · Liver International · doi:10.1111/liv.70051 · Cited by 6 · see citing works

Investigation on the mechanism of hepatotoxicity of dictamnine on juvenile zebrafish by integrating metabolomics and transcriptomics

Xu, X., Lü, F., Wang, Y., & Liu, S. (2024) · Gene · doi:10.1016/j.gene.2024.148826 · Cited by 5 · see citing works

Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy

Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i4.93606 · Cited by 4 · see citing works

Fatty liver index and somatic composition in subjects receiving medical health checkup

Ushiro, K., Matsui, M., Fukuda, A., Onishi, S., Nishikawa, T., Asai, A., Kim, S. K., & Nishikawa, H. (2024) · Hepatology Research · doi:10.1111/hepr.14127 · Cited by 4 · see citing works

Lipid nanosystems for fatty liver therapy and targeted medication delivery: a comprehensive review

Liang, C., Liu, X., Sun, Z., Wen, L., Wu, J., Shi, S., Liu, X., Luo, N., & Li, X. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125048 · Cited by 4 · see citing works

Estrogen–ER‐α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women

Cherubini, A., Casirati, E., Pelusi, S., & Valenti, L. V. C. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1524 · Cited by 4 · see citing works

Deciphering significances of autophagy in the development and metabolism of adipose tissue

Liu, Z., Peng, H., Liu, P., Duan, F., Yang, Y., Li, P., Li, Z., Wu, J., Chang, J., Shang, D., et al. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114478 · Cited by 3 · see citing works

Cell and gene therapeutic approaches in non-alcoholic fatty liver disease

Poudineh, M., Mohammadyari, F., Parsamanesh, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2025) · Gene · doi:10.1016/j.gene.2025.149466 · Cited by 3 · see citing works

Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation

Ocker, M., & Neureiter, D. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2288075 · Cited by 3 · see citing works

Evaluation of Metabolic Dysfunction-Associated Fatty Liver Disease-Related Pathogenic Mechanisms in Human Steatotic Liver Cell-Based Model: Beneficial Effects of Prunus domestica L. subsp. syriaca Extract

Comi, L., Giglione, C., Klinaku, F. T., Dalt, L. D., Ullah, H., Daglia, M., & Magni, P. (2025) · Nutrients · doi:10.3390/nu17071249 · Cited by 3 · see citing works

P5CS-coupled proline metabolism manipulates metabolic dysfunction-associated steatotic liver disease

Lyu, Z., Yu, S., Peng, C., Wu, W., Yang, W., Ma, H., Sun, Y., Jing, L., Gu, H., Tang, E., et al. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf040 · Cited by 2 · see citing works

Genetic Variants in Liver Cirrhosis: Classifications, Mechanisms, and Implications for Clinical Practice

Raghavan, R. P., Alexander, K. T., Sadasivan, S., Parmar, C. D., & Kathirvel, M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010029 · Cited by 2 · see citing works

The lack of apoA-I in apoE-KO mice affects the liver transcriptome

Franchi, E., Colombo, A., Manzini, S., Busnelli, M., & Chiesa, G. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103920 · Cited by 2 · see citing works

A Form of Metabolic-Associated Fatty Liver Disease Associated with a Novel LIPA Variant

Anushiravani, A., Khamirani, H. J., Mohamadkhani, A., Mani, A., Dianatpour, M., & Malekzadeh, R. (2023) · Archives of Iranian Medicine · doi:10.34172/aim.2023.14 · Cited by 2 · see citing works

Genetic and Lifestyle Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Relationship with Premature Coronary Artery Disease: A Study on the Pars Cohort

Anushiravani, A., Rayatpisheh, M., Kasaeian, A., & Oskouie, I. M. (2024) · Archives of Iranian Medicine · doi:10.34172/aim.2024.36 · Cited by 2 · see citing works

Association of PNPLA3 rs738409 C > G and rs2896019 T > G Polymorphisms with Nonalcoholic Fatty Liver Disease in a Turkish Population from Adıyaman Province

Bayram, S., & Ülger, Y. (2025) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2024.0481 · Cited by 1 · see citing works

Intestinal Activation of LXRα Counteracts Metabolic-Associated Steatohepatitis Features in Mice

Lioci, G., Gurrado, F., Panera, N., Bianchi, M., Stefanis, C. D., Doria, V., Cicolani, N., Santini, S. J., Schiadà, L., Alisi, A., et al. (2025) · Nutrients · doi:10.3390/nu17081349 · Cited by 1 · see citing works

Metabolic regulatory nodes of the inflammasome and inflammatory cell death

Lee, E., Nguyen, M. Q., Im, S., & Karki, R. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.06.002 · Cited by 1 · see citing works

Autophagy in MASLD : A Metabolic and Precision Medicine Perspective

Cazzaniga, A., Frigo, S., Cherubini, A., Rrapaj, E., & Valenti, L. V. C. (2026) · Liver International · doi:10.1111/liv.70816 · Cited by 1 · see citing works

Fatty liver disease genetic risk variants and interference on sex hormones

Tavaglione, F., Jamialahmadi, O., Valenti, L. V. C., & Romeo, S. (2023) · Liver International · doi:10.1111/liv.15562 · Cited by 1 · see citing works

Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities

Boeckmans, J., Gatzios, A., Schattenberg, J. M., Rodrigues, R. M., Rogiers, V., & Vanhaecke, T. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03498-0 · Cited by 1 · see citing works

A gene-by-sex interaction contributes to liver disease susceptibility in women

(2023) · Nature Medicine · doi:10.1038/s41591-023-02558-3 · Cited by 1 · see citing works

Editorial: Unveiling new horizons for liver steatosis genetic variants beyond hepatocellular carcinoma diagnosis ‐ exploring the potential of HSD17B13 inhibition

Valenti, L. V. C., & Casirati, E. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17664 · Cited by 1 · see citing works

Liver Steatosis: From Lipotoxicity to Cellular Damage

Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 1 · see citing works

Revolutionary Breakthroughs

Méndez‐Sánchez, N., & Ramírez-Mejía, M. M. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_10

Metabolic Syndrome and Somatic Composition: A Large Cross-sectional Analysis

MATSUI, M., FUKUDA, A., Onishi, S., Ushiro, K., NISHIKAWA, T., Asai, A., Kim, S. K., & Nishikawa, H. (2024) · In Vivo · doi:10.21873/invivo.13839

Association between IGF1 rs5742612 Polymorphism and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease

林, 于. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.152520

PNPLA3 in largemouth bass (Micropterus salmoides): Molecular cloning, functional characterization, and its role in high glucose-induced lipid synthesis

Yang, Y., Xu, Y.-Y., Ding, H., Ma, J.-M., Ai, Q., Zhou, L., & Xu, C. (2025) · Aquaculture Reports · doi:10.1016/j.aqrep.2025.102821

HLA DRB1*01 and *04 Predisposition to Rheumatoid Arthritis and Polymorphisms of the SLCO1B1, MTHFR and PNPLA3 Genes Are Not Associated with Fatty Liver and Hepatotoxicity

Zekić, T., Katalinić, N., Čizmarević, N. S., & Čubranić, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041568

Identification of PTPRR gene associated with cirrhosis and sarcopenia based on bioinformatics and machine learning

Ran, S., Li, H., Li, Z., Li, Y., Fang, Y., & Liu, B. (2026) · European Journal of Clinical Nutrition · doi:10.1038/s41430-026-01752-z

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review

Sozaeva, Z., Atayeva, M. V., Salatova, E. O., Alikova, I. K., Dolgaya, A. E., Magomedov, A., Hafsi, K. R., Shomakhov, N.-M. A., Pshukova, E., & Sharaf, Y. N. (2026) · Journal of biochemical technology · doi:10.51847/ybhmiqqb3d

Letter to the Editor: Enhancing fibrosis prediction in metabolic dysfunction-associated steatotic liver disease: The potential of combined biomarker approaches

Hu, H.-S., Lin-shu, X., & Sun, B.-Q. (2026) · World Journal of Hepatology · doi:10.4254/wjh.119430

Next-generation lipid nanoplatforms for phytoconstituent delivery in MASLD management

Apoorva, P. B., Kumar, B. S., & Paranthaman, S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108615

The association between physical activity and metabolic dysfunction–associated steatotic liver disease: Evidence from the National Health and Nutrition Examination Survey and UK Biobank

Shen, Y., Chen, M., Zhu, S., Lin, J., Liu, L., Zhu, C. K., Zhu, J., & Cm, X. (2026) · Journal of International Medical Research · doi:10.1177/03000605261467633

Targeting PNPLA3 I148M variant in MASLD: Cell-type specific mechanisms and precision therapy opportunities

Bu, H., Liu, L., Liu, H., Wang, H., & Wang, P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119746

The Human PNPLA3 I148M Polymorphism Alters the Renal Kinome and Transporters to Cause Hyperfiltration and Hypertension

Arthur, G., Adenawoola, M. I., Wahba, S., Montgomery, B., Wingfield, C. B., Kipp, Z. A., Hinds, T. D., & Stec, D. E. (2026) · FASEB BioAdvances · doi:10.1096/fba.2026-00222

An FDA‑approved dicarboxylic acid allosterically targets PNPLA3 to resolve osteoarthritis

Guan, Z., Zhao, K., Xiao, W., Guan, Z., Xiao, J., Yin, Q., Liu, S., Yin, Q., & Luo, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109644

siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges

Guo, Y., & Yao, Q. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102817

Pnpla3/Adiponutrin Deficiency in Mice Does Not Contribute to Steatohepatitis, Fibrosis or Cholestatic Liver Injury

McMahon, R., Claudel, T., Fuchs, C., Stojaković, T., Scharnagl, H., Zimmermann, R., Haemmerle, G., Kershaw, E. E., & Trauner, M. (2026) · International Journal of Negative Results · doi:10.14302/issn.2641-9181.ijnr-25-5844

PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease

Sookoian, S. C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i42.6018 · Cited by 64 · see citing works

PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease

Dong, X. C. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00304 · Cited by 86 · see citing works

PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease

Ray, S. B. (2019) · Adipocyte · doi:10.1080/21623945.2019.1607423 · Cited by 46 · see citing works

PNPLA3 I148M variant in nonalcoholic fatty liver disease: Demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis

Chen, L., Xin, Y., Geng, N., Jiang, M., Zhang, D., & Xuan, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.794 · Cited by 56 · see citing works

PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease

Wang, J., Cao, H., Chen, J.-N., & Pan, Q. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i8.167 · Cited by 38 · see citing works